PhAc-ALGP-Dox

• Description:

  PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells[1].

• UNSPSC:

  12352209

• Target:

  Peptide-Drug Conjugates (PDCs)

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/phac-algp-dox.html

• Smiles:

  OC1=C (C (C2=CC=CC (OC) =C2C3=O) =O) C3=C (O) C4=C1C[C@] (C (CO) =O) (O) C[C@@H]4O[C@H]5C[C@@H] ([C@@H] ([C@@H] (O5) C) O) NC ([C@H]6N (CCC6) C (CNC ([C@H] (CC (C) C) NC ([C@H] (C) NC (CP (O) (O) =O) =O) =O) =O) =O) =O

• Molecular Formula:

  C45H58N5O19P

• Molecular Weight:

  1003.94

• References & Citations:

  [1]Andrea Casazza, et al. PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. Mol Cancer Ther. 2022 Apr 1;21 (4) :568-581.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  1616592-31-4